糖尿病孕妇的母乳喂养模式:MOMPOD随机临床试验的二次分析

Pregnancy (Hoboken, N.J.) Pub Date : 2025-01-01 Epub Date: 2025-01-28 DOI:10.1002/pmf2.12040
Minhazur Sarker, Marni B Jacobs, Kim Boggess, Ashley N Battarbee, Jerrie Refuerzo, Noelia Zork, Kacey Eichelberger, Celeste Durnwald, Mark Landon, Kjersti Aagaard, Kedra Wallace, Christina Scifres, Sherri Longo, Alison Stuebe, Gladys A Ramos
{"title":"糖尿病孕妇的母乳喂养模式:MOMPOD随机临床试验的二次分析","authors":"Minhazur Sarker, Marni B Jacobs, Kim Boggess, Ashley N Battarbee, Jerrie Refuerzo, Noelia Zork, Kacey Eichelberger, Celeste Durnwald, Mark Landon, Kjersti Aagaard, Kedra Wallace, Christina Scifres, Sherri Longo, Alison Stuebe, Gladys A Ramos","doi":"10.1002/pmf2.12040","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Insulin resistance is associated with decreased milk supply in lactating people. Metformin is hypothesized to increase breast milk production by decreasing insulin resistance, suggesting use may increase breastfeeding success. We aimed to determine the association between metformin use during pregnancy and breastfeeding initiation and continuation.</p><p><strong>Methods: </strong>This was a secondary analysis of the MOMPOD randomized controlled trial of metformin versus placebo in addition to insulin therapy among pregnant people with type 2 diabetes and early diabetes. We included parturients who delivered a living neonate, received at least one dose of study drug or placebo, endorsed an intention to breastfeed, and completed a breastfeeding survey. Breastfeeding intentions and breastfeeding outcomes were collected utilizing a breastfeeding questionnaire at 24-30 weeks and 30-days postpartum respectively. The primary outcome was breastfeeding at 30-days postpartum defined by exclusive or partial breastfeeding. Secondary outcomes included immediate breastfeeding defined as any breastfeeding during the postpartum hospital admission until at least postpartum day 3, onset of lactogenesis (days), breast and bra size, and breastfeeding challenges. Baseline characteristics and outcomes were compared using chi-square, t-test, or Wilcoxon tests, as appropriate.</p><p><strong>Results: </strong>Among the 794 women randomized and receiving either placebo or metformin in the primary trial, 378 (47.6%) met inclusion criteria with 194 (51.3%) in metformin and 184 (48.7%) in placebo groups. There were no significant differences in baseline characteristics. Immediate breastfeeding was comparable between groups (91.1% vs 88.9%, p=0.53) and there was no difference in onset of lactogenesis. Thirty days postpartum, breastfeeding rates were lower among all parturients and there was no difference between metformin and placebo groups (76.0% vs 66.7%, p=0.11). Also, there were no differences in partial or exclusive breastfeeding, breast cup or bra size, or breastfeeding challenges.</p><p><strong>Conclusion: </strong>Our data suggest no association between metformin use and breastfeeding patterns in those with type 2 or early diabetes in pregnancy. Antepartum metformin should not be recommended solely to improve breastfeeding success.</p>","PeriodicalId":520540,"journal":{"name":"Pregnancy (Hoboken, N.J.)","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079847/pdf/","citationCount":"0","resultStr":"{\"title\":\"Breastfeeding patterns among parturients with diabetes: a secondary analysis of the MOMPOD randomized clinical trial.\",\"authors\":\"Minhazur Sarker, Marni B Jacobs, Kim Boggess, Ashley N Battarbee, Jerrie Refuerzo, Noelia Zork, Kacey Eichelberger, Celeste Durnwald, Mark Landon, Kjersti Aagaard, Kedra Wallace, Christina Scifres, Sherri Longo, Alison Stuebe, Gladys A Ramos\",\"doi\":\"10.1002/pmf2.12040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Insulin resistance is associated with decreased milk supply in lactating people. Metformin is hypothesized to increase breast milk production by decreasing insulin resistance, suggesting use may increase breastfeeding success. We aimed to determine the association between metformin use during pregnancy and breastfeeding initiation and continuation.</p><p><strong>Methods: </strong>This was a secondary analysis of the MOMPOD randomized controlled trial of metformin versus placebo in addition to insulin therapy among pregnant people with type 2 diabetes and early diabetes. We included parturients who delivered a living neonate, received at least one dose of study drug or placebo, endorsed an intention to breastfeed, and completed a breastfeeding survey. Breastfeeding intentions and breastfeeding outcomes were collected utilizing a breastfeeding questionnaire at 24-30 weeks and 30-days postpartum respectively. The primary outcome was breastfeeding at 30-days postpartum defined by exclusive or partial breastfeeding. Secondary outcomes included immediate breastfeeding defined as any breastfeeding during the postpartum hospital admission until at least postpartum day 3, onset of lactogenesis (days), breast and bra size, and breastfeeding challenges. Baseline characteristics and outcomes were compared using chi-square, t-test, or Wilcoxon tests, as appropriate.</p><p><strong>Results: </strong>Among the 794 women randomized and receiving either placebo or metformin in the primary trial, 378 (47.6%) met inclusion criteria with 194 (51.3%) in metformin and 184 (48.7%) in placebo groups. There were no significant differences in baseline characteristics. Immediate breastfeeding was comparable between groups (91.1% vs 88.9%, p=0.53) and there was no difference in onset of lactogenesis. Thirty days postpartum, breastfeeding rates were lower among all parturients and there was no difference between metformin and placebo groups (76.0% vs 66.7%, p=0.11). Also, there were no differences in partial or exclusive breastfeeding, breast cup or bra size, or breastfeeding challenges.</p><p><strong>Conclusion: </strong>Our data suggest no association between metformin use and breastfeeding patterns in those with type 2 or early diabetes in pregnancy. Antepartum metformin should not be recommended solely to improve breastfeeding success.</p>\",\"PeriodicalId\":520540,\"journal\":{\"name\":\"Pregnancy (Hoboken, N.J.)\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079847/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pregnancy (Hoboken, N.J.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pmf2.12040\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pregnancy (Hoboken, N.J.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pmf2.12040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在哺乳期人群中,胰岛素抵抗与乳汁供应减少有关。二甲双胍被假设通过降低胰岛素抵抗来增加母乳产量,这表明使用二甲双胍可能会增加母乳喂养的成功率。我们的目的是确定怀孕期间使用二甲双胍与母乳喂养开始和继续之间的关系。方法:这是MOMPOD随机对照试验的二次分析,二甲双胍与安慰剂加胰岛素治疗孕妇2型糖尿病和早期糖尿病。我们纳入了分娩了一个活的新生儿,接受了至少一剂研究药物或安慰剂,赞同母乳喂养的意图,并完成了母乳喂养调查的产妇。分别在产后24-30周和30天使用母乳喂养问卷收集母乳喂养意图和母乳喂养结果。主要结局是产后30天的母乳喂养,定义为纯母乳喂养或部分母乳喂养。次要结局包括立即母乳喂养,定义为产后入院期间至少至产后第3天的任何母乳喂养,乳发生开始(天),乳房和胸罩尺寸,以及母乳喂养挑战。基线特征和结果采用卡方检验、t检验或Wilcoxon检验进行比较。结果:在最初的试验中,794名随机接受安慰剂或二甲双胍治疗的女性中,378名(47.6%)符合纳入标准,其中二甲双胍组194名(51.3%),安慰剂组184名(48.7%)。两组的基线特征无显著差异。两组之间立即母乳喂养具有可比性(91.1% vs 88.9%, p=0.53),并且在乳发生的起始时间上没有差异。产后30天,所有产妇的母乳喂养率均较低,二甲双胍组与安慰剂组之间无差异(76.0% vs 66.7%, p=0.11)。此外,在部分或完全母乳喂养、乳房罩杯或胸罩尺寸或母乳喂养挑战方面也没有差异。结论:我们的数据表明孕期2型或早期糖尿病患者使用二甲双胍与母乳喂养模式之间没有关联。产前使用二甲双胍不应该仅仅是为了提高母乳喂养的成功率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Breastfeeding patterns among parturients with diabetes: a secondary analysis of the MOMPOD randomized clinical trial.

Introduction: Insulin resistance is associated with decreased milk supply in lactating people. Metformin is hypothesized to increase breast milk production by decreasing insulin resistance, suggesting use may increase breastfeeding success. We aimed to determine the association between metformin use during pregnancy and breastfeeding initiation and continuation.

Methods: This was a secondary analysis of the MOMPOD randomized controlled trial of metformin versus placebo in addition to insulin therapy among pregnant people with type 2 diabetes and early diabetes. We included parturients who delivered a living neonate, received at least one dose of study drug or placebo, endorsed an intention to breastfeed, and completed a breastfeeding survey. Breastfeeding intentions and breastfeeding outcomes were collected utilizing a breastfeeding questionnaire at 24-30 weeks and 30-days postpartum respectively. The primary outcome was breastfeeding at 30-days postpartum defined by exclusive or partial breastfeeding. Secondary outcomes included immediate breastfeeding defined as any breastfeeding during the postpartum hospital admission until at least postpartum day 3, onset of lactogenesis (days), breast and bra size, and breastfeeding challenges. Baseline characteristics and outcomes were compared using chi-square, t-test, or Wilcoxon tests, as appropriate.

Results: Among the 794 women randomized and receiving either placebo or metformin in the primary trial, 378 (47.6%) met inclusion criteria with 194 (51.3%) in metformin and 184 (48.7%) in placebo groups. There were no significant differences in baseline characteristics. Immediate breastfeeding was comparable between groups (91.1% vs 88.9%, p=0.53) and there was no difference in onset of lactogenesis. Thirty days postpartum, breastfeeding rates were lower among all parturients and there was no difference between metformin and placebo groups (76.0% vs 66.7%, p=0.11). Also, there were no differences in partial or exclusive breastfeeding, breast cup or bra size, or breastfeeding challenges.

Conclusion: Our data suggest no association between metformin use and breastfeeding patterns in those with type 2 or early diabetes in pregnancy. Antepartum metformin should not be recommended solely to improve breastfeeding success.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信